Life-science briefing: Tuesday, March 25, 2008
TODAY’S HEADLINES:
Antibody-discovery startup Adimab raises new funding (release)
Lung-device maker Spiration gets $19M (release)
Sample-prep startup Protein Discovery pulls in $10M (release)
Inogen takes in $13M for portable oxygen device (VentureWire)
Healthcare IT concern Medaptus raises $11M for expansion (VentureWire)
Contract lab Synexis raises $14M (peHUB)
Medical-device VC firm BioStar Ventures takes in $24M of $80M fund (peHUB)
Halsa Pharma gets $250K for “natural” obesity-control treatment (release)
Diagnostics provider Lab21 acquires NPTech (peHUB)
Galil Medical names Martin Emerson CEO (release)
Antibody-discovery startup Adimab raises new funding – Lebanon,… Continue Reading
Life sciences briefing: Friday, Feb. 29, 2008
TODAY’S HEADLINES:
Arriva Pharma recaps with $6M for respiratory anti-inflammatory drugs (release)
Genetic tester Sciona gets another $5.2M, distribution deal (VentureWire)
Joint resurfacer Arthrosurface takes in $4M (release)
Automated medication dispenser MDG Medical receives $14M in debt, equity (release)
California Stem Cell raises funds for heart, neurodegenerative treatments (release)
Arriva Pharma recaps with $6M for respiratory anti-inflammatory drugs – Arriva Pharmaceuticals, an Alameda, Calif., drug developer focused on inflammatory respiratory disease, raised $6 million in a convertible-stock funding that recapitalized the company…. Continue Reading
IPO roundup: MAP Pharma’s mixed reception, other recent filings
MAP Pharmaceuticals, the Mountain View, Calif., specialty pharma, had a mixed reception to its IPO Friday. The company priced its shares at $12, below its anticipated range of $14 to $16, raising up to $69 million — substantially less than the $92 million it might have pulled in. Investors, however, reacted positively and pushed up the shares 11 percent to $13.35.
MAP reformulates existing drugs in order to deliver them via inhalers. Its leading product is… Continue Reading
Lung-device maker Pulmonx draws in $20M
Palo Alto, Calif.-based Pulmonx raised $20 million in a second-round funding, VentureWire reports (subscription required).
The startup is one of several device makers hoping to pioneer new medical techniques in the field of “interventional pulmonology.” Much like interventional cardiology, in which non-surgeons perform procedures such as angioplasty and stenting to open blocked arteries, interventional pulmonology aims to give lung specialists new tools to treat lung problems such as emphysema in their offices. Patients, of course,… Continue Reading